Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in an equity round of funding on November 15, 2023. The transaction included participation from new investors, Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd. and Hangzhou Gongshu State Investment Industry Development Co., Ltd. for 8.57140% stake.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.77 CNY | +0.06% | +4.03% | -20.96% |
Apr. 25 | Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 18 | Huadong Medicine's 2023 Profit Jumps 14% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.96% | 7.91B | |
+17.35% | 71.39B | |
+2.39% | 25.1B | |
+5.38% | 8.59B | |
+6.69% | 8.19B | |
+0.49% | 4.54B | |
+17.12% | 4.31B | |
-2.61% | 3.86B | |
+22.08% | 3.64B | |
+7.96% | 3.29B |
- Stock Market
- Equities
- 000963 Stock
- News Huadong Medicine Co., Ltd
- Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd., Hangzhou Gongshu State Investment Industry Development Co., Ltd.